Sign in Subscribe
Johnson & Johnson

Johnson & Johnson MedTech Highlights Impella Heart Pump Innovations and Long-Term Survival Data at TCT 2025

Strategic Insights

— 2 min read

Johnson & Johnson MedTech, a global leader in heart recovery, showcased the latest long-term survival data confirming the Impella CP's survival benefit and presented the newest Impella innovations during the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco. The Impella heart pump, the world's smallest, is inserted into the heart to take over the pumping function, allowing patients to rest and recover while maintaining blood flow. This therapy enables patients to return to their lives and experience an equal or improved quality of life.

Key Takeaways:

  • Johnson & Johnson MedTech presented data from the DanGer Shock randomized controlled trial, published in The New England Journal of Medicine, confirming the long-term survival benefit of Impella CP, with an absolute mortality reduction of 16.3% compared to standard care at up to 10 years.
  • The Impella CP has been upgraded in recent multi-society guidelines, including ACC/AHA, for the treatment of cardiogenic shock patients.
  • The ninth generation Impella CP represents a decade of innovation, with design updates optimizing functionality and enhancing ease of use.
  • Impella has been highlighted and upgraded in global guidelines for both cardiology and surgery, including the American College of Cardiology/American Heart Association (ACC/AHA) guidelines for acute coronary syndrome.
  • The American Academy of Thoracic Surgery (AATS) Expert consensus statement elevated Impella recommendations in patients with acute myocardial infarction cardiogenic shock (AMICS) to Class 1.
  • The European Association for Cardio-Thoracic Surgeons, the American Association for Thoracic Surgery, and the Society for Thoracic Surgery released the first joint guidelines on temporary mechanical circulatory support, recommending Impella as a Class 1 intervention for adult patients with cardiogenic shock.
  • A lunch symposium, "Elevating your Clinical Practice for the New Era of Treating Cardiogenic Shock Patients," will be hosted by Heart Recovery on Monday, October 27, during the TCT World Connect Symposium.
  • The symposium will feature the latest from the OASIS trial, long-term DanGer RCT data, and shock escalation optimization.

Statistics:

  • Impella CP patients experienced an absolute mortality reduction of 16.3% compared to standard care at up to 10 years.
  • At up to 10 years, patients treated with Impella CP gained approximately 600 additional days alive compared to standard care.
  • Impella has been highlighted and upgraded in global guidelines for both cardiology and surgery.
  • 22 presentations will be showcased at TCT, featuring Impella data, including outcomes, real-world clinical experience, and long-term survival benefits.

Sources:

  • Moller, J., et al. (2024). Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock. N Engl J Med 2024; 390:1382-1393.
  • Rao, SV, et al. (2025). ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology.
  • Kaczorowski, D, et al. (2025). 2025 American Association for Thoracic Surgery (AATS) Expert Consensus Document: Surgical Management of acute myocardial infarction and associated complications. J Thoracic and CV Surgery.
  • Potapov, EV, et al. (2025). EACTS/STS/AATS Guidelines on temporary mechanical circulatory support in adult cardiac surgery. European Journal of Cardio-Thoracic Surgery.
  • Moller J, et al. Long Term Outcomes of the DanGer Shock Trial. N Engl J Med 2025
  • Moller J, et al. Long Term Outcomes of the DanGer Shock Trial. N Engl J Med 2025
  • Moller J, et al. Long Term Outcomes of the DanGer Shock Trial. N Engl J Med 2025

Read more